Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening

Sleep

Volumn 37, Issue 10, 2014, Pages 1715-1719B

  Rubio Sastre, Patricia ^a   Scheer, Frank A J L ^b,c   Gómez Abellán, Purificación ^a   Madrid, Juan A ^a   Garaulet, Marta ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Glucose tolerance; Insulin resistance; Melatonin; Metabolic syndrome; Oral glucose tolerance test

Indexed keywords

GLUCOSE; INSULIN; MELATONIN; PLACEBO; GLUCOSE BLOOD LEVEL;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; SINGLE BLIND PROCEDURE; ADULT; ANALYSIS; BLOOD; BODY MASS; CHEMICALLY INDUCED; CONTROLLED CLINICAL TRIAL; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; SECRETION (PROCESS); TIME; YOUNG ADULT;

ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; MELATONIN; SINGLE-BLIND METHOD; TIME FACTORS; YOUNG ADULT;

EID: 84907930175     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.5665/sleep.4088     Document Type: Article

References (26)

1. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2009;41:89-94.
2. Lyssenko V, Nagorny CL, Erdos MR, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 2009;41:82-8.
3. Prokopenko I, Langenberg C, Florez JC, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet 2009;41:77-81.
4. Lamberg L. Melatonin potentially useful but safety, efficacy remain uncertain. JAMA 1996;276:1011-4.
5. National Sleep Foundation. Summary of findings. 2005 Sleep in America Poll. Available at: http://www.sleepfoundation.org/sites/default/files/2005-summary-of-findings.pdf.
6. Cagnacci A, Arangino S, Renzi A, et al. Influence of melatonin administration on glucose tolerance and insulin sensitivity of postmenopausal women. Clin Endocrinol 2001;54:339-46.
7. Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes Metab Syndr Obes 2011;4:307-13.
8. Allison DB, Paultre F, Maggio C, Mezzitis N, Pi-Sunyer FX. The use of areas under curves in diabetes research. Diabetes Care 1995;18:245-50.
9. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-70.
10. Sluiter WJ, Erkelens DW, Reitsma WD, Doorenbos H. Glucose tolerance and insulin release, a mathematical approach I. Assay of the beta-cell response after oral glucose loading. Diabetes 1976;25:241-4.
11. Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000;151:190-8.
12. Peschke E, Bahr I, Muhlbauer E. Melatonin and Pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci 2013;14:6981-7015.
13. Kitagawa A, Ohta Y, Ohashi K. Melatonin improves metabolic syndrome induced by high fructose intake in rats. J Pineal Res 2012;52:403-13.
14. Agil A, Rosado I, Ruiz R, Figueroa A, Zen N, Fernandez-Vazquez G. Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res 2012;52:203-10.
15. McMullan CJ, Schernhammer ES, Rimm EB, Hu FB, Forman JP. Melatonin secretion and the incidence of type 2 diabetes. JAMA 2013;309:1388-96.
16. McMullan CJ, Schernhammer ES, Forman JP. Melatonin level and risk for type 2 diabetes - in reply. JAMA 2013;310:537.
17. Abbott SM, Zee PC. Melatonin level and risk for type 2 diabetes. JAMA 2013;310:536-7.
18. Sack RL, Auckley D, Auger RR, et al. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review. Sleep 2007;30:1484-501.
19. Burgess HJ, Revell VL, Molina TA, Eastman CI. Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. J Clin Endocrinol Metab 2010;95:3325-31.
20. Spiegel K, Tasali E, Leproult R, Van Cauter E. Effects of poor and short sleep on glucose metabolism and obesity risk. Nat Rev Endocrinol 2009;5:253-61.
21. Nedeltcheva AV, Scheer FA. Metabolic effects of sleep disruption, links to obesity and diabetes. Curr Opin Endocrinol Diabetes Obes 2014;21:293-8.
22. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet 1999;354:1435-9.
23. Hussain SA, Khadim HM, Khalaf BH, Ismail SH, Hussein KI, Sahib AS. Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin. Saudi Med J 2006;27:1483-8.
24. Basu A, Dalla Man C, Basu R, Toffolo G, Cobelli C, Rizza RA. Effects of type 2 diabetes on insulin secretion, insulin action, glucose effectiveness, and postprandial glucose metabolism. Diabetes Care 2009;32:866-72.
25. Garaulet M, Hernandez-Morante JJ, Tebar FJ, Zamora S, Canteras M. Two-dimensional predictive equation to classify visceral obesity in clinical practice. Obesity (Silver Spring) 2006;14:1181-91.
26. Diabetes care. Introduction. Diabetes Care 2013;36 Suppl 1:S1-2.